AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: AstraZeneca, in collaboration with Parexel, is conducting the ASTER study titled ‘Anifrolumab Study for Treatment Effectiveness in the Real World.’ This multi-national, observational study aims to evaluate the sustained clinical effects and quality of life outcomes for patients with Systemic Lupus Erythematosus (SLE) receiving anifrolumab in routine clinical practice. The study seeks to provide real-world evidence on the benefits of anifrolumab, aiding physicians, payers, and patients in treatment decisions.
Intervention/Treatment: The study focuses on anifrolumab, a treatment for SLE. As an observational study, it does not involve any experimental intervention but rather observes the effects of anifrolumab as prescribed in real-world settings.
Study Design: ASTER is a prospective, observational cohort study. It involves collecting data from patients who start anifrolumab treatment, with a follow-up period extending up to three years. The study uses electronic data collection methods to ensure consistent and secure data gathering.
Study Timeline: The study began on February 27, 2023, and is currently recruiting participants. The last update was submitted on July 22, 2025. These dates are crucial as they mark the progress and ongoing nature of the study, indicating its current recruitment status and future updates.
Market Implications: The ASTER study’s findings could significantly impact AstraZeneca’s stock performance by providing valuable real-world data supporting anifrolumab’s effectiveness, potentially boosting investor confidence. As the study progresses, it may influence market dynamics, especially in the competitive SLE treatment landscape.
The ASTER study is ongoing, with further details available on the ClinicalTrials portal.